These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16393445

  • 1. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [Abstract] [Full Text] [Related]

  • 2. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
    Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.
    Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP, VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [Abstract] [Full Text] [Related]

  • 4. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A, Williams GW, McKenna F, Fort JG.
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [Abstract] [Full Text] [Related]

  • 5. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
    Daniels SE, Desjardins PJ, Bird SR, Smugar SS, Tershakovec AM.
    Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG.
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [Abstract] [Full Text] [Related]

  • 7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 8. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
    Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ.
    Clin Ther; 1999 Oct 24; 21(10):1653-63. PubMed ID: 10566562
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
    Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M, CAPSS-114 Study Group.
    J Rheumatol; 2004 Jan 24; 31(1):150-6. PubMed ID: 14705234
    [Abstract] [Full Text] [Related]

  • 10. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR.
    Semin Arthritis Rheum; 2007 Dec 24; 37(3):164-73. PubMed ID: 17570469
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.
    Clin Ther; 2008 Dec 24; 30(12):2366-77. PubMed ID: 19167595
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 24; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 13. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun 24; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

  • 14. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O.
    Clin Ther; 2006 Sep 24; 28(9):1279-95. PubMed ID: 17062301
    [Abstract] [Full Text] [Related]

  • 15. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint.
    Park YG, Ha CW, Han CD, Bin SI, Kim HC, Jung YB, Lim HC.
    J Ethnopharmacol; 2013 Oct 07; 149(3):816-24. PubMed ID: 23954277
    [Abstract] [Full Text] [Related]

  • 16. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E, Hunsche E, Toubouti Y, Chabot I.
    Arthritis Rheum; 2006 Feb 15; 55(1):27-34. PubMed ID: 16463408
    [Abstract] [Full Text] [Related]

  • 17. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW.
    J Rheumatol; 2001 Nov 15; 28(11):2494-503. PubMed ID: 11708424
    [Abstract] [Full Text] [Related]

  • 18. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study.
    Cheung R, Krishnaswami S, Kowalski K.
    Clin Ther; 2007 Nov 15; 29 Suppl():2498-510. PubMed ID: 18164917
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain.
    Chelly JE, Nissen CW, Rodgers AJ, Smugar SS, Tershakovec AM.
    Curr Med Res Opin; 2007 Jan 15; 23(1):195-206. PubMed ID: 17207303
    [Abstract] [Full Text] [Related]

  • 20. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY, Tsai YW, Huang WF.
    Clin Ther; 2009 Nov 15; 31(11):2618-27. PubMed ID: 20110006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.